Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-'574) Antibody at the 2024 ECCO Annual Meeting -February 20, 2024 at 08:33 am EST
Results demonstrate rapid and sustained suppression of free TL1A, confirming target engagement of anti-TL1A 1 Anti-TL1A was shown to be safe and well-tolerated, with a low incidence of antidrug...
United States Eric Hughes Teva Pharmaceutical Industries Ltd Centers For Disease Colitis Organisation Teva Pharmaceuticals
Source: marketscreener.com